Cochlear Limited Logo

Cochlear Limited

CHEOY

(2.0)
Stock Price

97,34 USD

14.15% ROA

19.85% ROE

31.99x PER

Market Cap.

19.190.552.349,89 USD

11.54% DER

1.12% Yield

16.1% NPM

Cochlear Limited Stock Analysis

Cochlear Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cochlear Limited Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (17.75%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 DER

The stock has a low debt to equity ratio (15%), which means it has a small amount of debt compared to the ownership it holds

4 Dividend Growth

The company's dividend growth has been consistently strong over the past three years, with annual increases that demonstrate its commitment to rewarding shareholders.

5 Dividend

Investors can rely on the company's consistent dividend payments over the past three years, offering a steady stream of returns.

6 PBV

The stock's high Price-to-Book Value (P/BV) ratio (10.19x) suggests it's overvalued, potentially making it an expensive investment.

7 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

9 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

10 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-26) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Cochlear Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cochlear Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Cochlear Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Cochlear Limited Revenue
Year Revenue Growth
1995 72.275.000
1996 72.923.000 0.89%
1997 0 0%
1998 0 0%
1999 0 0%
2000 220.111.000 100%
2001 254.981.000 13.68%
2002 288.576.000 11.64%
2003 282.774.000 -2.05%
2004 344.854.000 18%
2005 452.260.000 23.75%
2006 559.412.000 19.15%
2007 601.725.000 7.03%
2008 694.699.000 13.38%
2009 734.803.000 5.46%
2010 809.646.000 9.24%
2011 778.996.000 -3.93%
2012 752.721.000 -3.49%
2013 804.936.000 6.49%
2014 925.630.000 13.04%
2015 1.130.552.000 18.13%
2016 1.253.838.000 9.83%
2017 1.363.700.000 8.06%
2018 1.426.700.000 4.42%
2019 1.320.600.000 -8.03%
2020 1.497.600.000 11.82%
2021 1.648.300.000 9.14%
2022 2.101.800.000 21.58%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Cochlear Limited Research and Development Expenses
Year Research and Development Expenses Growth
1995 11.015.000
1996 10.633.000 -3.59%
1997 0 0%
1998 0 0%
1999 0 0%
2000 27.742.000 100%
2001 42.977.000 35.45%
2002 37.030.000 -16.06%
2003 44.452.000 16.7%
2004 43.760.000 -1.58%
2005 58.926.000 25.74%
2006 65.949.000 10.65%
2007 78.374.000 15.85%
2008 96.498.000 18.78%
2009 94.881.000 -1.7%
2010 108.935.000 12.9%
2011 119.322.000 8.71%
2012 124.715.000 4.32%
2013 127.562.000 2.23%
2014 127.985.000 0.33%
2015 143.134.000 10.58%
2016 151.929.000 5.79%
2017 167.700.000 9.4%
2018 184.400.000 9.06%
2019 185.100.000 0.38%
2020 195.000.000 5.08%
2021 210.700.000 7.45%
2022 284.600.000 25.97%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Cochlear Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
1995 0
1996 1.764.000 100%
1997 0 0%
1998 0 0%
1999 0 0%
2000 15.435.000 100%
2001 10.665.000 -44.73%
2002 17.956.000 40.6%
2003 21.003.000 14.51%
2004 33.127.000 36.6%
2005 29.951.000 -10.6%
2006 38.635.000 22.48%
2007 36.092.000 -7.05%
2008 44.979.000 19.76%
2009 43.722.000 -2.87%
2010 43.699.000 -0.05%
2011 45.429.000 3.81%
2012 38.157.000 -19.06%
2013 44.162.000 13.6%
2014 53.862.000 18.01%
2015 79.287.000 32.07%
2016 83.474.000 5.02%
2017 97.400.000 14.3%
2018 94.800.000 -2.74%
2019 93.800.000 -1.07%
2020 112.200.000 16.4%
2021 159.000.000 29.43%
2022 220.800.000 27.99%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Cochlear Limited EBITDA
Year EBITDA Growth
1995 13.731.000
1996 14.964.000 8.24%
1997 18.100.000 17.33%
1998 26.787.000 32.43%
1999 33.830.000 20.82%
2000 46.673.000 27.52%
2001 56.927.000 18.01%
2002 88.553.000 35.71%
2003 61.668.000 -43.6%
2004 93.457.000 34.01%
2005 131.554.000 28.96%
2006 174.759.000 24.72%
2007 172.757.000 -1.16%
2008 187.824.000 8.02%
2009 227.910.000 17.59%
2010 250.536.000 9.03%
2011 161.677.000 -54.96%
2012 196.402.000 17.68%
2013 154.270.000 -27.31%
2014 236.960.000 34.9%
2015 296.563.000 20.1%
2016 347.556.000 14.67%
2017 385.400.000 9.82%
2018 409.300.000 5.84%
2019 -166.400.000 345.97%
2020 457.200.000 136.4%
2021 475.400.000 3.83%
2022 434.200.000 -9.49%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Cochlear Limited Gross Profit
Year Gross Profit Growth
1995 72.275.000
1996 72.923.000 0.89%
1997 0 0%
1998 0 0%
1999 0 0%
2000 147.692.000 100%
2001 182.015.000 18.86%
2002 223.473.000 18.55%
2003 206.901.000 -8.01%
2004 253.603.000 18.42%
2005 321.551.000 21.13%
2006 399.952.000 19.6%
2007 435.087.000 8.08%
2008 500.976.000 13.15%
2009 538.748.000 7.01%
2010 587.893.000 8.36%
2011 580.575.000 -1.26%
2012 546.131.000 -6.31%
2013 556.651.000 1.89%
2014 650.310.000 14.4%
2015 796.959.000 18.4%
2016 895.465.000 11%
2017 1.002.500.000 10.68%
2018 1.075.600.000 6.8%
2019 976.200.000 -10.18%
2020 1.087.400.000 10.23%
2021 1.237.300.000 12.12%
2022 1.579.600.000 21.67%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Cochlear Limited Net Profit
Year Net Profit Growth
1995 10.863.000
1996 10.809.000 -0.5%
1997 13.285.000 18.64%
1998 16.327.000 18.63%
1999 20.167.000 19.04%
2000 31.178.000 35.32%
2001 40.110.000 22.27%
2002 58.213.000 31.1%
2003 627.000 -9184.37%
2004 1.168.000 46.32%
2005 80.032.000 98.54%
2006 100.131.000 20.07%
2007 115.234.000 13.11%
2008 130.540.000 11.73%
2009 155.152.000 15.86%
2010 180.114.000 13.86%
2011 56.803.000 -217.09%
2012 132.563.000 57.15%
2013 93.709.000 -41.46%
2014 145.840.000 35.75%
2015 188.921.000 22.8%
2016 223.616.000 15.52%
2017 245.800.000 9.03%
2018 276.700.000 11.17%
2019 -238.300.000 216.11%
2020 326.500.000 172.99%
2021 289.100.000 -12.94%
2022 318.000.000 9.09%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cochlear Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 1 0%
2003 0 0%
2004 1 0%
2005 1 0%
2006 1 0%
2007 1 100%
2008 1 0%
2009 1 0%
2010 2 0%
2011 1 0%
2012 1 100%
2013 1 0%
2014 1 100%
2015 2 0%
2016 2 0%
2017 2 50%
2018 2 0%
2019 -2 200%
2020 2 200%
2021 2 0%
2022 5 50%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Cochlear Limited Free Cashflow
Year Free Cashflow Growth
1995 17.904.000
1996 4.204.000 -325.88%
1997 11.957.000 64.84%
1998 21.484.000 44.34%
1999 5.301.000 -305.28%
2000 14.224.000 62.73%
2001 -16.232.000 187.63%
2002 68.318.000 123.76%
2003 35.638.000 -91.7%
2004 87.194.000 59.13%
2005 36.341.000 -139.93%
2006 50.060.000 27.41%
2007 55.398.000 9.64%
2008 106.647.000 48.05%
2009 87.173.000 -22.34%
2010 110.763.000 21.3%
2011 130.836.000 15.34%
2012 19.308.000 -577.63%
2013 79.471.000 75.7%
2014 160.274.000 50.42%
2015 147.559.000 -8.62%
2016 188.702.000 21.8%
2017 208.400.000 9.45%
2018 181.400.000 -14.88%
2019 -288.300.000 162.92%
2020 192.799.999 249.53%
2021 299.300.000 35.58%
2022 121.800.000 -145.73%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Cochlear Limited Operating Cashflow
Year Operating Cashflow Growth
1995 19.478.000
1996 6.233.000 -212.5%
1997 14.252.000 56.27%
1998 25.799.000 44.76%
1999 11.060.000 -133.26%
2000 19.761.000 44.03%
2001 898.000 -2100.56%
2002 78.817.000 98.86%
2003 48.970.000 -60.95%
2004 98.634.000 50.35%
2005 51.555.000 -91.32%
2006 76.836.000 32.9%
2007 84.548.000 9.12%
2008 146.628.000 42.34%
2009 179.546.000 18.33%
2010 201.277.000 10.8%
2011 168.280.000 -19.61%
2012 69.727.000 -141.34%
2013 111.417.000 37.42%
2014 188.701.000 40.96%
2015 185.113.000 -1.94%
2016 259.772.000 28.74%
2017 258.100.000 -0.65%
2018 296.000.000 12.8%
2019 -157.800.000 287.58%
2020 265.399.999 159.46%
2021 376.500.000 29.51%
2022 136.650.000 -175.52%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Cochlear Limited Capital Expenditure
Year Capital Expenditure Growth
1995 1.574.000
1996 2.029.000 22.42%
1997 2.295.000 11.59%
1998 4.315.000 46.81%
1999 5.759.000 25.07%
2000 5.537.000 -4.01%
2001 17.130.000 67.68%
2002 10.499.000 -63.16%
2003 13.332.000 21.25%
2004 11.440.000 -16.54%
2005 15.214.000 24.81%
2006 26.776.000 43.18%
2007 29.150.000 8.14%
2008 39.981.000 27.09%
2009 92.373.000 56.72%
2010 90.514.000 -2.05%
2011 37.444.000 -141.73%
2012 50.419.000 25.73%
2013 31.946.000 -57.83%
2014 28.427.000 -12.38%
2015 37.554.000 24.3%
2016 71.070.000 47.16%
2017 49.700.000 -43%
2018 114.600.000 56.63%
2019 130.500.000 12.18%
2020 72.600.000 -79.75%
2021 77.200.000 5.96%
2022 14.850.000 -419.87%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Cochlear Limited Equity
Year Equity Growth
1995 18.456.000
1996 23.307.000 20.81%
1997 32.095.000 27.38%
1998 34.050.000 5.74%
1999 42.829.000 20.5%
2000 55.495.000 22.82%
2001 75.416.000 26.41%
2002 119.687.000 36.99%
2003 139.018.000 13.91%
2004 161.129.000 13.72%
2005 207.537.000 22.36%
2006 260.809.000 20.43%
2007 319.341.000 18.33%
2008 364.234.000 12.33%
2009 438.308.000 16.9%
2010 503.283.000 12.91%
2011 384.880.000 -30.76%
2012 356.913.000 -7.84%
2013 329.205.000 -8.42%
2014 355.386.000 7.37%
2015 448.557.000 20.77%
2016 543.647.000 17.49%
2017 610.800.000 10.99%
2018 725.900.000 15.86%
2019 1.401.500.000 48.21%
2020 1.701.700.000 17.64%
2021 1.685.700.000 -0.95%
2022 1.748.800.000 3.61%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Cochlear Limited Assets
Year Assets Growth
1995 48.242.000
1996 51.287.000 5.94%
1997 69.113.000 25.79%
1998 82.939.000 16.67%
1999 93.771.000 11.55%
2000 129.048.000 27.34%
2001 160.428.000 19.56%
2002 230.579.000 30.42%
2003 264.539.000 12.84%
2004 505.747.000 47.69%
2005 545.924.000 7.36%
2006 585.737.000 6.8%
2007 607.916.000 3.65%
2008 679.373.000 10.52%
2009 751.719.000 9.62%
2010 741.047.000 -1.44%
2011 702.542.000 -5.48%
2012 764.501.000 8.1%
2013 789.036.000 3.11%
2014 869.056.000 9.21%
2015 957.363.000 9.22%
2016 1.136.359.000 15.75%
2017 1.156.900.000 1.78%
2018 1.379.200.000 16.12%
2019 2.575.700.000 46.45%
2020 2.438.200.000 -5.64%
2021 2.465.100.000 1.09%
2022 2.568.700.000 4.03%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cochlear Limited Liabilities
Year Liabilities Growth
1995 29.786.000
1996 27.980.000 -6.45%
1997 37.018.000 24.42%
1998 48.889.000 24.28%
1999 50.942.000 4.03%
2000 73.553.000 30.74%
2001 85.012.000 13.48%
2002 110.892.000 23.34%
2003 119.010.000 6.82%
2004 339.877.000 64.98%
2005 336.146.000 -1.11%
2006 324.928.000 -3.45%
2007 288.575.000 -12.6%
2008 315.139.000 8.43%
2009 313.411.000 -0.55%
2010 237.764.000 -31.82%
2011 317.662.000 25.15%
2012 407.588.000 22.06%
2013 459.831.000 11.36%
2014 513.670.000 10.48%
2015 508.806.000 -0.96%
2016 592.712.000 14.16%
2017 546.100.000 -8.54%
2018 653.300.000 16.41%
2019 1.174.200.000 44.36%
2020 736.500.000 -59.43%
2021 779.400.000 5.5%
2022 819.900.000 4.94%

Cochlear Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
29.5
Net Income per Share
4.58
Price to Earning Ratio
31.99x
Price To Sales Ratio
9.91x
POCF Ratio
26.53
PFCF Ratio
61.43
Price to Book Ratio
5.5
EV to Sales
9.73
EV Over EBITDA
42.06
EV to Operating CashFlow
51.98
EV to FreeCashFlow
60.3
Earnings Yield
0.03
FreeCashFlow Yield
0.02
Market Cap
19,19 Bil.
Enterprise Value
18,84 Bil.
Graham Number
52.4
Graham NetNet
4.73

Income Statement Metrics

Net Income per Share
4.58
Income Quality
1.21
ROE
0.17
Return On Assets
0.14
Return On Capital Employed
0.24
Net Income per EBT
0.75
EBT Per Ebit
0.97
Ebit per Revenue
0.22
Effective Tax Rate
0.25

Margins

Sales, General, & Administrative to Revenue
0.11
Research & Developement to Revenue
0.13
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.75
Operating Profit Margin
0.22
Pretax Profit Margin
0.22
Net Profit Margin
0.16

Dividends

Dividend Yield
0.01
Dividend Yield %
1.12
Payout Ratio
0.66
Dividend Per Share
1.1

Operating Metrics

Operating Cashflow per Share
5.52
Free CashFlow per Share
4.76
Capex to Operating CashFlow
-0.14
Capex to Revenue
-0.03
Capex to Depreciation
-0.7
Return on Invested Capital
0.14
Return on Tangible Assets
0.14
Days Sales Outstanding
82.48
Days Payables Outstanding
202.25
Days of Inventory on Hand
232.99
Receivables Turnover
4.43
Payables Turnover
1.8
Inventory Turnover
1.57
Capex per Share
-0.76

Balance Sheet

Cash per Share
9,85
Book Value per Share
26,65
Tangible Book Value per Share
19.88
Shareholders Equity per Share
26.65
Interest Debt per Share
3.07
Debt to Equity
0.12
Debt to Assets
0.08
Net Debt to EBITDA
-0.79
Current Ratio
2.36
Tangible Asset Value
1,30 Bil.
Net Current Asset Value
0,54 Bil.
Invested Capital
0.12
Working Capital
0,78 Bil.
Intangibles to Total Assets
0.17
Average Receivables
0,22 Bil.
Average Payables
0,27 Bil.
Average Inventory
311500000
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cochlear Limited Dividends
Year Dividends Growth
2010 0
2011 1 100%
2012 1 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 0 0%
2017 1 100%
2018 1 0%
2019 1 0%
2021 1 0%
2022 1 100%
2023 1 0%

Cochlear Limited Profile

About Cochlear Limited

Cochlear Limited provides implantable hearing solutions for adults and children worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company was founded in 1981 and is headquartered in Sydney, Australia.

CEO
Mr. Diggory William Howitt BE
Employee
4.800
Address
1 University Avenue
Sydney, 2109

Cochlear Limited Executives & BODs

Cochlear Limited Executives & BODs
# Name Age
1 Rob McGrory
Group General Counsel
70
2 Ms. Kristina Devon
Vice President of Investor Relations
70
3 Ms. Jennifer Stevenson
Vice President of Corporate Communications & Brand
70
4 Mr. Diggory William Howitt BE (Hons), MBA
Chief Executive Officer, MD, President & Executive Director
70
5 Mr. Greg Bodkin BE (Hons), MComm (UNSW)
Senior Vice President of Global Supply Chain
70
6 Ms. Jennifer Hornery
Senior Vice President of Global People & Culture
70
7 Mr. Dean Phizacklea
Senior Vice President of Global Strategic Marketing
70
8 Mr. Stuart Sayers
Chief Financial Officer
70
9 Mr. Jan Janssen MSc Elec Eng
Chief Technology Officer
70
10 Ms. Karen O'Driscoll
Chief Information Officer
70

Cochlear Limited Competitors